NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Forecast & News

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its earnings results on Wednesday, November, 6th. The company reported $0.18 earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.49. The firm had revenue of $168 million for the quarter, compared to analyst estimates of $152.47 million. Ionis Pharmaceuticals had a net margin of 52.26% and a return on equity of 36.31%. The company's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.03) EPS. View Ionis Pharmaceuticals' Earnings History.

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Ionis Pharmaceuticals.

12 analysts have issued twelve-month target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $48.00 to $120.00. On average, they expect Ionis Pharmaceuticals' share price to reach $75.82 in the next year. This suggests a possible upside of 26.1% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ionis Pharmaceuticals.

Media stories about IONS stock have trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Ionis Pharmaceuticals.

Ionis Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 8,480,000 shares, an increase of 10.1% from the December 31st total of 7,700,000 shares. Based on an average daily volume of 983,700 shares, the days-to-cover ratio is presently 8.6 days. Approximately 6.6% of the shares of the stock are sold short. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), BlackRock (BLK), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Allergan (AGN).

Ionis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.90%), Baillie Gifford & Co. (6.25%), BVF Inc. IL (1.55%), Renaissance Technologies LLC (1.45%), First Trust Advisors LP (0.71%) and Sumitomo Mitsui Trust Holdings Inc. (0.69%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Pictet Asset Management Ltd., UBS Group AG, Jacobs Levy Equity Management Inc., Pinnacle Associates Ltd., Bank of America Corp DE, Rafferty Asset Management LLC and Goldman Sachs Group Inc.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Rockefeller Capital Management L.P., Baillie Gifford & Co., Scout Investments Inc., Renaissance Technologies LLC, Rothschild & Co. Asset Management US Inc., Sumitomo Mitsui Trust Holdings Inc. and Amia Capital LLP. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $60.13.

Ionis Pharmaceuticals has a market capitalization of $8.46 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.